News about "Sun Pharma "

Sun Pharma Receives Approval to Manufacture and Market Generic Semaglutide in South Africa

Sun Pharma has received approval to manufacture and market generic semaglutide in South Africa, available as a once-weekly pre-filled multi-dose injectable pen in 2 strengths.

Sun Pharma | 15/07/2026 | By News Bureau

Sun Pharma to Acquire Innovcare Lifesciences in INR 271 Crore Strategic Deal

Sun Pharma will acquire Innovcare Lifesciences for INR 271.2 crore, strengthening its presence in pharmaceuticals, nutraceuticals, and cosmeceuticals through the acquisition of the Mumbai-based healthcare company.

Sun Pharma | 22/06/2026 | By News Bureau

Alembic Pharma Names Ramesh Juneja as EVP, Human Health

Alembic Pharmaceuticals has appointed Ramesh Juneja as Executive Vice President–Human Health for its India business. Bringing leadership experience from Sun Pharma, Cipla and Reliance Retail, Juneja will spearhead sales and marketing initiatives to drive growth in Alembic’s domestic pharmaceutical business.

Sun Pharma | 02/06/2026 | By News Bureau |  103

Sun Pharma Launches Semaglutide Injection in India Under Noveltreat and Sematrinity

Sun Pharmaceutical Industries has introduced semaglutide injections in India under the brands Noveltreat and Sematrinity, expanding access to advanced therapies for chronic weight management and type 2 diabetes. The launch strengthens treatment options with multiple dose strengths tailored to patient needs alongside diet and lifestyle interventions.

Sun Pharma | 21/03/2026 | By News Bureau |  690

Sun Pharma Announces US FDA Acceptance of sBLA Application for ILUMYA to Treat Adults with Active Psoriatic Arthritis

The US FDA has accepted Sun Pharma’s supplemental BLA for ILUMYA to treat active psoriatic arthritis in adults, with a decision expected by 29 October, 2026, potentially expanding its IL-23 inhibitor portfolio.

Sun Pharma | 17/03/2026 | By News Bureau |  147

MHRA Clears Deuruxolitinib (Leqselvi) by Sun Pharma for Severe Alopecia Areata in Adults

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved deuruxolitinib (Leqselvi) for treating severe Alopecia Areata in adults, granting authorisation to Sun Pharma UK via the International Recognition Procedure (IRP).

Sun Pharma | 13/03/2026 | By News Bureau |  123

Sun Pharma to Invest Rs 500 Crore in Expansion of Assam Manufacturing Unit

Sun Pharmaceutical Industries said it will invest Rs 500 crore to expand its manufacturing facility in Assam, aiming to strengthen its domestic production infrastructure and support future growth.

Sun Pharma | 06/02/2026 | By Darshana |  205

Sun Pharma Wins DCGI Nod for Generic Semaglutide Injection

Sun Pharmaceutical has secured approval from the Drugs Controller General of India (DCGI) to manufacture and market a generic semaglutide injection for chronic weight management, paving the way for its entry into the fast-growing obesity treatment segment once the semaglutide patent expires in the country.

Sun Pharma | 27/01/2026 | By News Bureau |  226

Sun Pharma Launches UNLOXCYT for Advanced Cutaneous Squamous Cell Carcinoma

Sun Pharma has announced the US availability of UNLOXCYT for adults with metastatic or locally advanced cutaneous squamous cell carcinoma who are not eligible for curative surgery or radiation. The updated label includes long-term data supporting durable efficacy and a favourable tolerability profile.

Sun Pharma | 16/01/2026 | By News Bureau |  130

Sun Pharma Introduces ILUMYA in India for Plaque Psoriasis Treatment

Sun Pharma has launched its global innovative drug, ILUMYA (Tildrakizumab), in India for the treatment of moderate-to-severe plaque psoriasis.

Sun Pharma | 01/12/2025 | By Dineshwori |  196